Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 4

Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes

Authors Aristoteles A N Giagounidis, Ulrich Germing, Sabine Haase, Carlo Aul

Published 15 September 2007 Volume 2007:3(4) Pages 553—562

Aristoteles A N Giagounidis, Ulrich Germing1, Sabine Haase, Carlo Aul

Medizinische Klinik II, St. Johannes Hospital, Duisburg, Germany. 1Klinik für Hämatologie, Onkologie und Immunologie, Heinrich-Heine- Universität, Düsseldorf, Germany

Abstract: Lenalidomide is a novel thalidomide analogue with enhanced immunomodulatory and antiangiogenic action lacking most of the typical thalidomide-associated adverse events. In myelodysplastic syndromes (MDS), it has been used primarily in the IPSS low- and intermediate-1 risk setting. Several trials have demonstrated its potential to lead to both erythroid and cytogenetic responses in these disease groups. In a clinical trial of patients with a del(5q) chromosomal abnormality, lenalidomide treatment resulted in red blood cell (RBC) transfusion independence in 67% of patients. Moreover, 45% of patients achieved a complete cytogenetic remission, and 28% achieved a minor cytogenetic remission. This result was independent of karyotype complexity. Lenalidomide might also induce long-term remissions in del(5q) patients with an elevated medullary blast count. In non-del(5q) patients, 43% of patients with confirmed low- and intermediate-1 risk achieved transfusion independence or a reduction of at least 50% of pre-treatment RBC transfusion levels. Adverse events are common but manageable and include neutropenia and thrombocytopenia, pruritus, rash, diarrhea, and others. Lenalidomide will prove an essential part in the armamentarium of MDS therapeutics. Combination therapies with cytokines, demethylating agents, tyrosine kinase inhibitors, or chemotherapy are being investigated and may show additional benefit in both low- and high risk MDS.

Keywords: Lenalidomide, myelodysplastic syndromes, therapy, clinical trials

Download Article [PDF] 

Readers of this article also read:

Paclitaxel attenuates renal interstitial fibroblast activation and interstitial fibrosis by inhibiting STAT3 signaling

Zhang L, Xu X, Yang R, Chen J, Wang S, Yang JQ, Xiang X, He Z, Zhao Y, Dong Z, Zhang D

Drug Design, Development and Therapy 2015, 9:2139-2148

Published Date: 15 April 2015

In vitro cytotoxicity of the ternary PAMAM G3–pyridoxal–biotin bioconjugate

Uram Ł, Szuster M, Gargasz K, Filipowicz A, Wałajtys-Rode E, Wołowiec S

International Journal of Nanomedicine 2013, 8:4707-4720

Published Date: 11 December 2013

Treatment of atopic dermatitis with pimecrolimus – impact on quality of life

Hae-Hyuk Lee, Torsten Zuberbier, Margitta Worm

Therapeutics and Clinical Risk Management 2007, 3:1021-1026

Published Date: 15 January 2008

Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors

Jean-Pierre Armand, Vincent Ribrag, Jean-Luc Harrousseau, Lauren Abrey

Therapeutics and Clinical Risk Management 2007, 3:213-224

Published Date: 15 May 2007

Efficacy of Bacillus clausii spores in the prevention of recurrent respiratory infections in children: a pilot study

Gian Luigi Marseglia, Mariangela Tosca, Ignazio Cirillo, Amelia Licari, Maddalena Leone, Alessia Marseglia, Anna Maria Castellazzi, Giorgio Ciprandi

Therapeutics and Clinical Risk Management 2007, 3:13-17

Published Date: 15 March 2007